Clin2
NCT06564584Possibly a fitRecruiting

Study of TLC-2716 for high triglycerides and fatty liver disease

HypertriglyceridemiaNonalcoholic Fatty Liver Disease

Part of Digestive system, Hormones & metabolism clinical trials.

This trial tests an investigational drug called TLC-2716 for people with very high triglycerides and a type of fatty liver disease (NAFLD or NASH). The goal is to see if it is safe and can help lower fat levels in the blood and liver.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You have a body mass index (BMI) of 28 or higher
  • Your fasting triglycerides are 350 mg/dL or more
  • You have been diagnosed with fatty liver disease (NAFLD/NASH) in the last 5 years
  • You either do not have diabetes, or if you do, your blood sugar control (HbA1c) is below 9.5%
  • You have not lost more than 5% of your body weight in the last 3 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07028749Recruiting· Phase 2
Study of an experimental drug for high triglycerides and remnant cholesterol

This trial tests an investigational medication, MAR001, to see if it can lower high levels of fats in the blood (triglycerides and remnant cholesterol) linked to heart disease. If you have these conditions, this treatment might help reduce your risk.

Anniston, Alabama
NCT06891365Recruiting· Phase 1
Multiple doses of a new drug for fatty liver disease

This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.

Harrow
NCT07214870Recruiting· Phase 1
A study of a new medicine for liver disease in adults with extra body weight and liver fat

This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.

Montreal, Quebec
NCT03468556Not yet recruiting· Phase 2
Drug trial for non-alcoholic fatty liver inflammation (NASH)

This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.

NCT07198386Recruiting· Phase 2
Study of CS060380 tablets for NASH (fatty liver disease)

This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.

Fuzhou, Fujian
NCT07766759Not yet recruiting· Phase 1
Study of an experimental drug for adults with high triglycerides

This early-phase trial tests an experimental drug called FXR0906 in healthy adults who have elevated triglycerides (a type of fat in the blood). It aims to see if the drug is safe and how it affects cholesterol and fat levels, which may help prevent heart disease.

Beijing, Beijing Municipality

Hear when a new Hypertriglyceridemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.